Compounds > irinotecan

Page last updated: 2024-08-24

irinotecan and verapamil

irinotecan has been researched along with verapamil in 19 studies

Research

Studies (19)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (10.53)	18.2507
2000's	7 (36.84)	29.6817
2010's	9 (47.37)	24.3611
2020's	1 (5.26)	2.80

Authors

Authors	Studies
Dansette, PM; Fontana, E; Poli, SM	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Lombardo, F; Obach, RS; Waters, NJ	1
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L	1
Chen, X; Lin, X; Skolnik, S; Wang, J	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Bellman, K; Knegtel, RM; Settimo, L	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Cowan, KH; Fukuda, M; Ikeda, K; Kohno, S; Matsuo, I; Nakano, R; Narasaki, F; Oka, M; Soda, H; Takatani, H; Terashi, K; Tomonaga, M	1
Boven, E; Giaccone, G; Hulscher, TM; Jansen, WJ; Pinedo, HM; van Ark-Otte, J	1
de Bruijn, P; de Jonge, MJ; Kurihara, M; Nishiyama, M; Sparreboom, A; Takano, H; Verweij, J; Yamamoto, W	1
Bansal, T; Jaggi, M; Khar, RK; Mishra, G; Talegaonkar, S	1
Li, G; Li, M; Rabba, AK; Si, L; Xue, K	1
Ambudkar, SV; Bhatnagar, J; Chen, JJ; Chen, WM; Chen, ZS; Lan, P; Ruan, ZX; Shu, C; Sodani, K; Wang, J; Xiao, ZJ; Ye, WC; Zhang, DM	1
Guo, D; Guo, J; Huang, S; Li, Q; Polli, JE; Shu, Y; Xiong, Z; Ye, Z; Zhang, W; Zhou, H; Zhu, P	1
Arimori, K; Furuya, Y; Hidaka, M; Kawano, Y; Ono, H; Yamasaki, K	1

Reviews

3 review(s) available for irinotecan and verapamil

Article	Year
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Current drug metabolism, 2005, Volume: 6, Issue:5 Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic	2005
Membrane transporters in drug development. Nature reviews. Drug discovery, 2010, Volume: 9, Issue:3 Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs	2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

16 other study(ies) available for irinotecan and verapamil

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11 Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:2 Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity	2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds. Pharmaceutical research, 2014, Volume: 31, Issue:4 Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation	2014
The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers. Japanese journal of cancer research : Gann, 1996, Volume: 87, Issue:12 Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; Doxorubicin; Etoposide; Genes, MDR; Humans; Irinotecan; Mitomycin; Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Verapamil; Vincristine	1996
CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. British journal of cancer, 1998, Volume: 77, Issue:3 Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Camptothecin; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Mice; Multidrug Resistance-Associated Proteins; RNA, Messenger; Tumor Cells, Cultured; Verapamil	1998
Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells. Anti-cancer drugs, 2001, Volume: 12, Issue:5 Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzazepines; Biological Transport; Biotransformation; Caco-2 Cells; Camptothecin; Cell Survival; Chromatography, High Pressure Liquid; Cyclosporine; Humans; Intestinal Mucosa; Irinotecan; Quinolines; RNA, Messenger; Verapamil	2001
Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2009, Mar-02, Volume: 36, Issue:4-5 Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Biliary Tract; Caco-2 Cells; Calcium Channel Blockers; Camptothecin; Chromatography, High Pressure Liquid; Female; Humans; Irinotecan; Rats; Rats, Wistar; Spectrophotometry, Ultraviolet; Verapamil	2009
In Situ intestinal perfusion of irinotecan: application to P-gp mediated drug interaction and introduction of an improved HPLC assay. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2011, Volume: 14, Issue:2 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calibration; Camptothecin; Chromatography, High Pressure Liquid; Drug Interactions; Drug Stability; Intestinal Absorption; Intestinal Mucosa; Intestines; Irinotecan; Male; Perfusion; Rats; Rats, Sprague-Dawley; Topoisomerase I Inhibitors; Verapamil	2011
BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo. Molecular pharmaceutics, 2012, Nov-05, Volume: 9, Issue:11 Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Breast Neoplasms; Calcium Channel Blockers; Camptothecin; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorescent Antibody Technique; Humans; In Vitro Techniques; Irinotecan; KB Cells; Liver Neoplasms; Male; Mice; Mice, Nude; Models, Molecular; Molecular Docking Simulation; Paclitaxel; Piperidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triterpenes; Verapamil	2012
Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2). Pharmaceutical research, 2018, Oct-25, Volume: 35, Issue:12 Topics: Amitriptyline; Animals; Drug Interactions; Fluoxetine; HEK293 Cells; Humans; Imipramine; Irinotecan; Mice, Inbred C57BL; Morphine; Narcotics; Ondansetron; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Tissue Distribution; Verapamil	2018
Possible roles of intestinal P-glycoprotein and cytochrome P450 3A on the limited oral absorption of irinotecan. The Journal of pharmacy and pharmacology, 2021, Mar-04, Volume: 73, Issue:2 Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cytochrome P-450 CYP3A; Intestinal Absorption; Irinotecan; Male; Rats; Rats, Wistar; Topoisomerase I Inhibitors; Verapamil	2021